New SmartState Endowed Chair to Develop Cancer Drugs in SC
Top scientist based at S.C. College of Pharmacy, helps lead state’s Cancer Drug Discovery Center of Economic Excellence
One of the nation’s leading cancer drug researchers has moved his work to South Carolina thanks to the state’s SmartState Program (previously known as the CoEE Program).
Dr. Patrick Woster is based at the S.C. College of Pharmacy (SCCP), where he helps lead the Center of Economic Excellence in Cancer Drug Discovery as the SmartState Endowed Chair in Medicinal Chemistry.Woster is one of four endowed chairs supported by the Cancer Drug Discovery Center, a Medical University of South Carolina (MUSC) Center in which the University of South Carolina is a partner.
The SCCP has five endowed chairs overall: Chuck Smith (drug discovery), John Lemasters (cell injury, death and regeneration), Charles Bennett (medication safety and efficacy), Igor Roninson (translational cancer therapeutics) and Woster (drug discovery).
“We are excited to have a medicinal chemist of Dr. Woster’s caliber join our drug discovery team,” says Rick Schnellmann, chair of the Department of Pharmaceutical and Biomedical Sciences at SCCP.
Woster works to develop drugs that turn specific genes on or off in tumor cells, a process known as epigenetic modulation, that can make anti-tumor medications more effective. In addition, he and his team work to discover new treatments for diseases such as malaria and other parasitic illnesses.
“We have a goal of developing a world-class drug discovery program at MUSC by providing a core facility for drug synthesis and compound development, and by teaming up with existing centers within the university, such as Hollings Cancer Center,” says Woster. To date, Woster holds eight patents based on compounds he has synthesized.
“The discovery of successful, improved agents for the treatment of cancer would have a significant impact on the lives of patients in South Carolina and beyond,” Woster explains. “We hope to increase the scope of our research efforts to include many aspects of the drug development process that will ultimately lead to early and late human clinical trials.”
Woster’s work could have a notable impact on quality of life in South Carolina by leading to improvements in both the physical well-being of cancer patients and in the economic health of the state through the creation of new companies and new job opportunities.
“Creating new intellectual property is an important aspect of our work, and we hope to exploit the commercial potential of our agents through association with or creation of new companies within the state of South Carolina,” he says. Woster also notes that the compounds developed through his work could be “of significant interest to large pharmaceutical firms, especially in the current environment where alliances between industry and academia have become much more common.”
Woster’s interest in cancer drug research began during a clinical rotation in a hospital oncology unit while in pharmacy school.
“I witnessed the fear and confusion that patients experienced following a diagnosis of cancer, and the frustration of the medical staff, who at that time had a very limited arsenal of drugs for chemotherapy,” says Woster. “Most of these drugs had very serious side effects, and in many cases only prolonged the life of the patient for a short time. These observations were major motivating factors in my decision to train as a researcher.”
Woster says he was drawn to South Carolina because of the reputation of MUSC as an emerging power in biomedical research, the outstanding reputation of SCCP, and the state’s SmartState Program, which provides an opportunity for Woster to advance his research to the next level of excellence and promote economic development in South Carolina.
“I’ve been impressed with the collaborative environment that exists here,” said Woster, who arrived on campus March 1. “I’ve already seen lots of possible opportunities to collaborate on new projects.”
“We are thrilled to recruit a recognized leader in cancer research as an Endowed Chair,” says SmartState Review Board Chair Pamela P. Lackey. “Dr. Woster’s work has great potential to touch many lives in this state and to advance the biosciences industry in South Carolina.”
About the SmartState Program
The South Carolina SmartState™ Program (previously known as the CoEE Program) was created by the South Carolina legislature in 2002 and is funded through South Carolina Education Lottery proceeds. The legislation authorizes the state's three public research institutions, Medical University of South Carolina, Clemson University and the University of South Carolina, to use state funds to create Centers of Economic Excellence in research areas that will advance South Carolina's economy. Each Center of Economic Excellence is awarded from $2 million to $5 million in state lottery funds, which must be matched on a dollar-for-dollar basis with non-state investment. To date, 49 Centers have been created and 35 SmartState Endowed Chairs have been appointed to lead the centers. The SmartState Program has resulted in more than $375 million dollars in non-state investment into the South Carolina economy and is responsible for the creation of more than 4,700 jobs. www.SmartStateSC.org .
About S.C. College of Pharmacy
The South Carolina College of Pharmacy (SCCP) was formed in 2004 through the integration of the Colleges of Pharmacy at the University of South Carolina in Columbia (USC) and the Medical University of South Carolina in Charleston (MUSC). The SCCP is a statewide education, research, and service institution that combines the nationally recognized faculty, staff, and resources of MUSC, a major academic medical center, and USC, a large comprehensive university, to create a statewide approach to pharmacy education that is on a par with some of the most highly regarded colleges in the United States.